Il vaccino per il coronavirus arriverà nei prossimi mesi. È fondamentale che sia reso disponibile a tutti e a prezzi accessibili. Per questo si deve evitare che le industrie farmaceutiche facciano enormi profitti appropriandosi privatamente del frutto di ricerche di base finanziate da soldi pubblici.
The search for treatments and vaccines to curb transmission of the new coronavirus is in overdrive. Fortunately, there are a number of promising candidates thanks to the U.S. government’s investment in biomedical research and development.
Since the 2003 SARS outbreak, the United States has spent nearly $700 million of taxpayer money on coronavirus research — more than any other country — through the National Institutes of Health. Yet the question right now for Americans — thousands of whom are forced to ration their insulin and face astronomical bills for live-saving drugs — is not only when these treatments and vaccines will become available, but at what price.
As the world’s leader in public financing of biomedical research, the U.S. government has the opportunity to set a precedent to ensure that medicines developed with public funding are accessible and affordable to the public; this will have enormous implications not only how for we deal with the coronavirus, but also for the crisis of unaffordable medicines in America.
Health Secretary Alex Azar recently said that he could not guarantee coronavirus treatments or vaccines would be affordable, despite taxpayers’ significant investment in their development. Faced with public backlash led by the House speaker, Nancy Pelosi, Mr. Azar backtracked, although details on how the administration would keep prices down remain unclear.
One way was spelled out in a letter sent on Feb. 20 by 46 lawmakers: It demands that coronavirus vaccines and treatments developed with taxpayer money should be produced without giving an exclusive license to private manufacturers.
